A Compound That Inhibits Glycolysis in Prostate Cancer Controls Growth of Advanced Prostate Cancer

Scientists reported the preclinical activity, safety, and pharmacokinetics of a novel small molecule preclinical candidate, BKIDC-1553, with antiglycolytic activity. A human PDX model implanted in mice and a human organoid was studied for sensitivity to our BKIDC preclinical candidate.